Can single-cell analyses generate signatures of disease endotypes for discovery/validation of drug targets within specific IBD patient subsets? Can single-cell analyses further the discovery or validation of biomarkers in blood or bulk tissue? How can single-cell analyses be scaled from small single-center studies to multicenter studies? Login for a fascinating discussion.
Abigail J. Meyers, PA-CPeer